Switzerland
Switzerland-based Nouscom AG has appointed Göran Ando as chair of its board of directors and Richard Davis as chief business officer. The appointments come as the company starts clinical development of its lead cancer vaccine. Dr Ando is currently chair of the specialty pharma company EyePoint Pharmaceuticals Inc as well as chair of Tessa Therapeutics Ltd, which is developing cell therapies for cancer. His more than 35 years in biopharma management have also included senior positions at Pfizer Inc, GlaxoSmithKline Plc and Celltech Group Ltd.
Dr Davis joins Nouscom from Johnson & Johnson Innovation. Earlier in his career he was an executive at the Wellcome Trust.
Nouscom announced the appointments on 11 December 2020.
Copyright 2020 Evernow Publishing Ltd